Tempest Therapeutics (TPST) vs Universe Pharmaceuticals (UPC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Universe Pharmaceuticals (UPC) has outperformed Tempest Therapeutics (TPST) over the past year, losing 68.2% versus a loss of 91.8%. Over five years, TPST leads with a -99.8% price change compared with -100.0% for UPC. Tempest Therapeutics is the larger company by market cap ($5.7 million vs $5.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TPST | UPC |
|---|---|---|
| Share price | $0.287 | $1.08 |
| Market cap | $5.74M | $5.43M |
| 1-day change | -6.18% | -20.59% |
| YTD return | -90.00% | -71.65% |
| 1-year return | -91.80% | -68.24% |
| 5-year return | -99.77% | -99.99% |
| EPS (TTM) | $-3.16 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $17.86B |
| Revenue growth (YoY) | — | -22.44% |
| Net income (latest FY) | $-26.26M | $-3.67B |
| Gross margin | — | 35.28% |
| Operating margin | — | -16.33% |
| Net margin | — | -20.56% |
| 52-week high | $4.22 | $17.96 |
| 52-week low | $0.28 | $1.05 |
| Distance from 52-week high | -93.20% | -93.99% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +2339.02% | — |
| Average volume | 2.56M | 176.76K |
| Shares outstanding | 20.00M | 5.01M |
| Employees | 4 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UPC has outperformed TPST by 23.6 percentage points over the past year.
About Tempest Therapeutics
TPST stock →Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Universe Pharmaceuticals
UPC stock →Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
TPST vs UPC FAQ
Which is bigger, Tempest Therapeutics or Universe Pharmaceuticals?
Tempest Therapeutics (TPST) is larger, with a market capitalization of $5.74M compared with $5.43M for Universe Pharmaceuticals (UPC).
Which stock has performed better over the past year, TPST or UPC?
UPC returned -68.24% over the past 12 months, compared with -91.80% for TPST (price return, excluding dividends). Past performance does not predict future results.
Are Tempest Therapeutics and Universe Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.